Vasomune is a private biopharmaceutical company developing the next generation of medications to harness the body’s ability to defend against illness.
Joined November 2019
- Tweets 58
- Following 591
- Followers 108
- Likes 28
18 Photos and videos
Pinned Tweet
3 Sep 2025
77
3 Sep 2025
Health Canada approves a new trial for Pegevongitide (AV-001) — a made-in-Canada therapy co-developed by Vasomune & AnGes — to protect hemodialysis patients from brain injury by stabilizing the cerebrovasculature.
1
141
Vasomune Therapeutics, Inc. retweeted
27 Sep 2024
🧬Next up as part of our #GlobalBiotechWeek celebration is @vasomune who reached the milestone of receiving U.S. FDA Fast Track Designation for their novel investigational medicine AV-001. 👏🏽 We're proud of Vasomune, an #OBIO member, as they continue to advance to the next phase!
1
2
141
20 Sep 2024
Vasomune Therapeutics, Inc. is proud to be in Florida presenting our work at the 2024 Military Health System Research Symposium! With their support we have come a long way from preclinical to Phase 2a with AV-001 for the prevention and treatment of ARDS.
linkedin.com/posts/haroldkim…
1
76
15 Aug 2024
Thank you @ARDSALliance and @PaulaBlonski for striving against ARDS, and for reminding us why continued research into prevention and treatment is so important.
linkedin.com/posts/paulablon…
2
61
13 Aug 2024
MHSRS-24-11804 (Full title in article) at 2024 Military Health System Research Symposium. Read more in the link below.
linkedin.com/feed/update/urn…
50
Vasomune Therapeutics, Inc. retweeted
26 Jun 2024
👏🏽Congratulations to @vasomune on this milestone! We are proud of #OBIO member, Vasomune, as they receive U.S. FDA Fast Track Designation for AV-001. Looking forward to seeing you advance to the next phase!
28 May 2024
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 businesswire.com/news/home/2…
3
5
289
Ft. @brogoz (CEO of @oncoustics), Alison Smith (co-founder and chief scientist at Roga), @FelixBL92 (CEO of @altislabs), Adam Forman (co-founder of Synakis) and Brian Jahns (COO of @vasomune).
1
3
476
These five startups are working on solutions that could speed up diagnosis, develop promising new therapeutics and improve patient care. Check them out at #MaRSImpactHealth happening June 12 and 13.
marsdd.com/news/meet-5-entre…
1
5
12
765
Vasomune Therapeutics, Inc. retweeted
6 Jun 2024
This week @AstraZeneca completed the acquisition of Genesys portfolio company @FusionPharmaInc for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals.
prnewswire.com/news-releases…
1
4
200
3 Jun 2024
On Monday, June 5th at 3pm PST, Dr Brian Jahns presents the Vasomune Therapeutics story. Join Brian in Theatre 3 for the story of how Vasomune achieved the Fast Track Designation for pneumonia ARDS, and what his vision for the future is.
convention.bio.org/sessions/…
53
28 May 2024
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001 businesswire.com/news/home/2…
5
594
Vasomune Therapeutics, Inc. retweeted
8 May 2024
アンジェス---Vasomuneとの共同開発品「AV-001」が米国呼吸器学会でポスター発表 - 最新株式ニュース dlvr.it/T6ZnpF
1
1
119
8 May 2024
On May 21, 2024, Vasomune's Dr. Harold Kim will present Phase 1 safety, and pharmacokinetic and pharmacodynamic data for AV-001 as a late-breaking scientific poster at the American Thoracic Society Clinical and Scientific sessions.
lnkd.in/gYM4HPAk
99
8 May 2024
Vasomune Therapeutics' Dr Harold Kim, has been selected by the American Thoracic Society to showcase our lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit. Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA.
1
100
14 Nov 2023
We are pleased to announce that the Independent Data and Safety Monitoring Board recommended the continuation of the Phase 2a trial (NCT05123755) evaluating the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory... businesswire.com/news/home/2…
1
4
1,528
18 Jan 2022
Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease.
businesswire.com/news/home/2…
1
8
19
8 Nov 2021
Our strategic approach to SARS-CoV-2 involves the development of AV-001 for treating patients with severe COVID-19 disease and vaccines to prevent infection businesswire.com/news/home/2…
1
10